The Myriad Gene Patent Case – What does it Mean, and Why Does it Matter?
Source
Genetic Alliance Webinars
Description
A high-profile lawsuit aimed at invalidating gene patents, American Molecular Pathology et al v. US Patent and Trade Office, Myriad Genetics, recently reached an important stage. A federal district court granted summary judgment to the plaintiffs and ruled that Myriad Genetics’ patents on the BRAC 1/2 breast cancer genes and related method claims do not cover patentable subject matter and thus are invalid.Professor John Conley of the University of North Carolina School of Law will moderate a frank discussion between Hans Sauer of BIO, which opposes the plaintiffs’ position, and Josh Sarnoff, who filed an amicus brief on behalf of the American Medical Association supporting the plaintiffs. We invite you to listen closely to disparate points of view – in hopes that as we listen, we can collectively move closer to common ground.
Date Added
May 10, 2010
Keywords
Webinar 2010, Myriad Gene Patent, gene patenting, April 30
Posted by